Shopping Cart 0
Cart Subtotal
AED 0

Diabetic Foot Ulcers - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 7340

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 14680

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 22020
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Diabetic Foot Ulcers-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Foot Ulcers-Pipeline Review, H2 2018, provides an overview of the Diabetic Foot Ulcers (Metabolic Disorders) pipeline landscape.

Diabetic foot ulcers are sores that occur on the feet of people with Type 1 Diabetes and Type 2 Diabetes. Symptoms include sores, ulcers, or blisters on the foot or lower leg, pain, walking with difficulty, discoloration in feet: black, blue, or red, cold feet and fever, skin redness or swelling, or other signs of infection. The predisposing factors include diabetic neuropathy, peripheral vascular disease, a foot deformity and history of tobacco use disorder.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Foot Ulcers-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Foot Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 12, 9, 1, 16, 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Foot Ulcers (Metabolic Disorders).

- The pipeline guide reviews pipeline therapeutics for Diabetic Foot Ulcers (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Diabetic Foot Ulcers (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Diabetic Foot Ulcers (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Foot Ulcers (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Diabetic Foot Ulcers (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

Introduction 5

Diabetic Foot Ulcers-Overview 6

Diabetic Foot Ulcers-Therapeutics Development 7

Diabetic Foot Ulcers-Therapeutics Assessment 17

Diabetic Foot Ulcers-Companies Involved in Therapeutics Development 25

Diabetic Foot Ulcers-Drug Profiles 37

Diabetic Foot Ulcers-Dormant Projects 118

Diabetic Foot Ulcers-Discontinued Products 122

Diabetic Foot Ulcers-Product Development Milestones 123

Appendix 132


List Of Figure

List of Figures

Number of Products under Development for Diabetic Foot Ulcers, H2 2018 12

Number of Products under Development by Companies, H2 2018 13

Number of Products by Top 10 Targets, H2 2018 22

Number of Products by Stage and Top 10 Targets, H2 2018 22

Number of Products by Top 10 Mechanism of Actions, H2 2018 24

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018 24

Number of Products by Routes of Administration, H2 2018 26

Number of Products by Stage and Routes of Administration, H2 2018 26

Number of Products by Top 10 Molecule Types, H2 2018 28

Number of Products by Stage and Top 10 Molecule Types, H2 2018 28


List Of Table

List of Tables

Number of Products under Development for Diabetic Foot Ulcers, H2 2018 12

Number of Products under Development by Companies, H2 2018 14

Number of Products under Development by Universities/Institutes, H2 2018 17

Products under Development by Companies, H2 2018 18

Products under Development by Universities/Institutes, H2 2018 21

Number of Products by Stage and Target, H2 2018 23

Number of Products by Stage and Mechanism of Action, H2 2018 25

Number of Products by Stage and Route of Administration, H2 2018 27

Number of Products by Stage and Molecule Type, H2 2018 29

Diabetic Foot Ulcers-Pipeline by Anterogen Co Ltd, H2 2018 30

Diabetic Foot Ulcers-Pipeline by CardioVascular BioTherapeutics Inc, H2 2018 30

Diabetic Foot Ulcers-Pipeline by Celularity Inc, H2 2018 31

Diabetic Foot Ulcers-Pipeline by Cynata Therapeutics Ltd, H2 2018 31

Diabetic Foot Ulcers-Pipeline by CytoTools AG, H2 2018 32

Diabetic Foot Ulcers-Pipeline by Energenesis Biomedical Co Ltd, H2 2018 32

Diabetic Foot Ulcers-Pipeline by EyeGene Inc, H2 2018 32

Diabetic Foot Ulcers-Pipeline by Factor Therapeutics Ltd, H2 2018 33

Diabetic Foot Ulcers-Pipeline by FirstString Research Inc, H2 2018 33

Diabetic Foot Ulcers-Pipeline by Genentech Inc, H2 2018 34

Diabetic Foot Ulcers-Pipeline by Human Stem Cells Institute, H2 2018 34

Diabetic Foot Ulcers-Pipeline by Lakewood-Amedex Inc, H2 2018 34

Diabetic Foot Ulcers-Pipeline by MallInckrodt Plc, H2 2018 35

Diabetic Foot Ulcers-Pipeline by MediWound Ltd, H2 2018 35

Diabetic Foot Ulcers-Pipeline by NovaLead Pharma Pvt Ltd, H2 2018 36

Diabetic Foot Ulcers-Pipeline by OliX Pharmaceuticals Inc, H2 2018 36

Diabetic Foot Ulcers-Pipeline by Oneness Biotech Co Ltd, H2 2018 37

Diabetic Foot Ulcers-Pipeline by Pherecydes Pharma SA, H2 2018 37

Diabetic Foot Ulcers-Pipeline by ProMetic Life Sciences Inc, H2 2018 38

Diabetic Foot Ulcers-Pipeline by Promore Pharma AB, H2 2018 38

Diabetic Foot Ulcers-Pipeline by Shionogi & Co Ltd, H2 2018 38

Diabetic Foot Ulcers-Pipeline by Stempeutics Research Pvt Ltd, H2 2018 39

Diabetic Foot Ulcers-Pipeline by SynDermix AG, H2 2018 39

Diabetic Foot Ulcers-Pipeline by TechnoPhage SA, H2 2018 40

Diabetic Foot Ulcers-Pipeline by Topadur Pharma AG, H2 2018 40

Diabetic Foot Ulcers-Pipeline by USV Pvt Ltd, H2 2018 40

Diabetic Foot Ulcers-Pipeline by ViroMed Co Ltd, H2 2018 41

Diabetic Foot Ulcers-Pipeline by ZZ Biotech LLC, H2 2018 41

Diabetic Foot Ulcers-Dormant Projects, H2 2018 123

Diabetic Foot Ulcers-Discontinued Products, H2 2018 127

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Diabetic Foot Ulcers Therapeutic Products under Development, Key Players in Diabetic Foot Ulcers Therapeutics, Diabetic Foot Ulcers Pipeline Overview, Diabetic Foot Ulcers Pipeline, Diabetic Foot Ulcers Pipeline Assessment


Companies

Anterogen Co Ltd

CardioVascular BioTherapeutics Inc

Celularity Inc

Cynata Therapeutics Ltd

CytoTools AG

Energenesis Biomedical Co Ltd

EyeGene Inc

Factor Therapeutics Ltd

FirstString Research Inc

Genentech Inc

Human Stem Cells Institute

Lakewood-Amedex Inc

MallInckrodt Plc

MediWound Ltd

NovaLead Pharma Pvt Ltd

OliX Pharmaceuticals Inc

Oneness Biotech Co Ltd

Pherecydes Pharma SA

ProMetic Life Sciences Inc

Promore Pharma AB

Shionogi & Co Ltd

Stempeutics Research Pvt Ltd

SynDermix AG

TechnoPhage SA

Topadur Pharma AG

USV Pvt Ltd

ViroMed Co Ltd

ZZ Biotech LLC

Diabetic Foot Ulcers-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Foot Ulcers-Pipeline Review, H2 2018, provides an overview of the Diabetic Foot Ulcers (Metabolic Disorders) pipeline landscape.

Diabetic foot ulcers are sores that occur on the feet of people with Type 1 Diabetes and Type 2 Diabetes. Symptoms include sores, ulcers, or blisters on the foot or lower leg, pain, walking with difficulty, discoloration in feet: black, blue, or red, cold feet and fever, skin redness or swelling, or other signs of infection. The predisposing factors include diabetic neuropathy, peripheral vascular disease, a foot deformity and history of tobacco use disorder.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Foot Ulcers-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Foot Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 12, 9, 1, 16, 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Foot Ulcers (Metabolic Disorders).

- The pipeline guide reviews pipeline therapeutics for Diabetic Foot Ulcers (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Diabetic Foot Ulcers (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Diabetic Foot Ulcers (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Foot Ulcers (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Diabetic Foot Ulcers (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Table of Contents 2

Introduction 5

Diabetic Foot Ulcers-Overview 6

Diabetic Foot Ulcers-Therapeutics Development 7

Diabetic Foot Ulcers-Therapeutics Assessment 17

Diabetic Foot Ulcers-Companies Involved in Therapeutics Development 25

Diabetic Foot Ulcers-Drug Profiles 37

Diabetic Foot Ulcers-Dormant Projects 118

Diabetic Foot Ulcers-Discontinued Products 122

Diabetic Foot Ulcers-Product Development Milestones 123

Appendix 132


List Of Figure

List of Figures

Number of Products under Development for Diabetic Foot Ulcers, H2 2018 12

Number of Products under Development by Companies, H2 2018 13

Number of Products by Top 10 Targets, H2 2018 22

Number of Products by Stage and Top 10 Targets, H2 2018 22

Number of Products by Top 10 Mechanism of Actions, H2 2018 24

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018 24

Number of Products by Routes of Administration, H2 2018 26

Number of Products by Stage and Routes of Administration, H2 2018 26

Number of Products by Top 10 Molecule Types, H2 2018 28

Number of Products by Stage and Top 10 Molecule Types, H2 2018 28


List Of Table

List of Tables

Number of Products under Development for Diabetic Foot Ulcers, H2 2018 12

Number of Products under Development by Companies, H2 2018 14

Number of Products under Development by Universities/Institutes, H2 2018 17

Products under Development by Companies, H2 2018 18

Products under Development by Universities/Institutes, H2 2018 21

Number of Products by Stage and Target, H2 2018 23

Number of Products by Stage and Mechanism of Action, H2 2018 25

Number of Products by Stage and Route of Administration, H2 2018 27

Number of Products by Stage and Molecule Type, H2 2018 29

Diabetic Foot Ulcers-Pipeline by Anterogen Co Ltd, H2 2018 30

Diabetic Foot Ulcers-Pipeline by CardioVascular BioTherapeutics Inc, H2 2018 30

Diabetic Foot Ulcers-Pipeline by Celularity Inc, H2 2018 31

Diabetic Foot Ulcers-Pipeline by Cynata Therapeutics Ltd, H2 2018 31

Diabetic Foot Ulcers-Pipeline by CytoTools AG, H2 2018 32

Diabetic Foot Ulcers-Pipeline by Energenesis Biomedical Co Ltd, H2 2018 32

Diabetic Foot Ulcers-Pipeline by EyeGene Inc, H2 2018 32

Diabetic Foot Ulcers-Pipeline by Factor Therapeutics Ltd, H2 2018 33

Diabetic Foot Ulcers-Pipeline by FirstString Research Inc, H2 2018 33

Diabetic Foot Ulcers-Pipeline by Genentech Inc, H2 2018 34

Diabetic Foot Ulcers-Pipeline by Human Stem Cells Institute, H2 2018 34

Diabetic Foot Ulcers-Pipeline by Lakewood-Amedex Inc, H2 2018 34

Diabetic Foot Ulcers-Pipeline by MallInckrodt Plc, H2 2018 35

Diabetic Foot Ulcers-Pipeline by MediWound Ltd, H2 2018 35

Diabetic Foot Ulcers-Pipeline by NovaLead Pharma Pvt Ltd, H2 2018 36

Diabetic Foot Ulcers-Pipeline by OliX Pharmaceuticals Inc, H2 2018 36

Diabetic Foot Ulcers-Pipeline by Oneness Biotech Co Ltd, H2 2018 37

Diabetic Foot Ulcers-Pipeline by Pherecydes Pharma SA, H2 2018 37

Diabetic Foot Ulcers-Pipeline by ProMetic Life Sciences Inc, H2 2018 38

Diabetic Foot Ulcers-Pipeline by Promore Pharma AB, H2 2018 38

Diabetic Foot Ulcers-Pipeline by Shionogi & Co Ltd, H2 2018 38

Diabetic Foot Ulcers-Pipeline by Stempeutics Research Pvt Ltd, H2 2018 39

Diabetic Foot Ulcers-Pipeline by SynDermix AG, H2 2018 39

Diabetic Foot Ulcers-Pipeline by TechnoPhage SA, H2 2018 40

Diabetic Foot Ulcers-Pipeline by Topadur Pharma AG, H2 2018 40

Diabetic Foot Ulcers-Pipeline by USV Pvt Ltd, H2 2018 40

Diabetic Foot Ulcers-Pipeline by ViroMed Co Ltd, H2 2018 41

Diabetic Foot Ulcers-Pipeline by ZZ Biotech LLC, H2 2018 41

Diabetic Foot Ulcers-Dormant Projects, H2 2018 123

Diabetic Foot Ulcers-Discontinued Products, H2 2018 127

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Diabetic Foot Ulcers Therapeutic Products under Development, Key Players in Diabetic Foot Ulcers Therapeutics, Diabetic Foot Ulcers Pipeline Overview, Diabetic Foot Ulcers Pipeline, Diabetic Foot Ulcers Pipeline Assessment


Companies

Anterogen Co Ltd

CardioVascular BioTherapeutics Inc

Celularity Inc

Cynata Therapeutics Ltd

CytoTools AG

Energenesis Biomedical Co Ltd

EyeGene Inc

Factor Therapeutics Ltd

FirstString Research Inc

Genentech Inc

Human Stem Cells Institute

Lakewood-Amedex Inc

MallInckrodt Plc

MediWound Ltd

NovaLead Pharma Pvt Ltd

OliX Pharmaceuticals Inc

Oneness Biotech Co Ltd

Pherecydes Pharma SA

ProMetic Life Sciences Inc

Promore Pharma AB

Shionogi & Co Ltd

Stempeutics Research Pvt Ltd

SynDermix AG

TechnoPhage SA

Topadur Pharma AG

USV Pvt Ltd

ViroMed Co Ltd

ZZ Biotech LLC

chat_bubbleLet's Chat